Table 3 The autoantibody profile of myositis patients and the distribution of HFA-PEFF score tertiles in each subgroup
HFA-PEFF score tertiles | Low | Intermediate | High | p-value |
|---|---|---|---|---|
Myositis-specific antibodies (MSAs), n (%) | ||||
 Anti-MDA5 | 18(32.7%) | 29(52.7%) | 8(14.5%) | 0.335 |
 Anti-Jo1 | 17(38.6%) | 24(54.5%) | 3(6.8%) | |
 Anti-EJ | 5(31.3%) | 8(50.0%) | 3(18.8%) | |
 Anti-PL7 | 7(33.3%) | 10(47.6%) | 4(19.0%) | |
 Anti-PL12 | 5(38.5%) | 6(46.2%) | 2(15.4%) | |
 Anti-SRP | 5(23.8%) | 8(38.1%) | 8(38.1%) | |
 Anti-HMGCR | 5(55.6%) | 2(22.2%) | 2(22.2%) | |
 Anti-TIF1γ | 2(22.2%) | 4(44.4%) | 3(33.3%) | |
 Anti-Mi2 | 2(33.3%) | 3(50.0%) | 1(16.7%) | |
 Anti-NXP2 | 1(33.3%) | 2(66.7%) | 0(0.0%) | |
 Anti-SAE | 1(25.0%) | 3(75.0%) | 0(0.0%) | |
 MSA negative | 11(57.9%) | 8(42.1%) | 0(0.0%) |  |
Myositis-associated antibodies (MAAs), n (%) | ||||
 Anti-Ku | 3(33.3%) | 5(55.6%) | 1(11.1%) | 0.894 |
 Anti-PMScl75/100 | 8(36.4%) | 11(50.0%) | 3(13.6%) | 0.969 |
 AMA-M2 | 2(11.1%) | 10(55.6%) | 6(33.3%) | 0.011 |
 Anti-Ro52 | 37(30.3%) | 67(54.9%) | 18(14.8%) | 0.096 |